Cytotoxic effect of clodronate and zoledronate on the chondrosarcoma cell lines HTB-94 and CAL-78

International Orthopaedics

Volumn 35, Issue 9, 2011, Pages 1369-1373

  Streitbuerger, Arne ^a   Henrichs, Marcel ^a   Ahrens, Helmut ^a   Lanvers Kaminzky, Claudia ^a   Gouin, Francois ^b   Gosheger, Georg ^a   Hardes, Jendrik ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLODRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; CAL 78 CELL; CELL PROLIFERATION; CELL STRAIN; CELL VIABILITY; CHONDROSARCOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; HTB 94 CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; SARCOMA CELL;

AGED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHONDROSARCOMA; CLODRONIC ACID; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FORMAZANS; HUMANS; IMIDAZOLES; MALE; TETRAZOLIUM SALTS;

EID: 80655128439     PISSN: 03412695     EISSN: 14325195     Source Type: Journal    
DOI: 10.1007/s00264-010-1130-5     Document Type: Article

References (28)

1. Rozeman LB, Cleton-Jansen AM, Hogendoorn PCW (2006) Pathology of primary mailgnant bone and cartilage tumours. Int Orthop 30:437-444 (Pubitemid 44900549)
2. Fiorenza F, Abudu A, Grimer RJ, Carter SR, Tillman R, Ayoub K et al (2002) Risk factors for survival and local control in chondrosarcoma of bone. J Bone Joint Surg Br 84(1):93-99 (Pubitemid 34105631)
3. Brown JE, Neville-Webbe H, Coleman RE (2004) The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 11(2):207-224 (Pubitemid 38832826)
4. Coleman RE (2002) Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials. Am J Clin Oncol 25(6 Suppl 1):25-31
5. Berenson JR, Lipton A (1999) Bisphosphonates in the treatment of malignant bone disease. Annu Rev Med 50:237-248 (Pubitemid 29117064)
6. Rosen L, Harland SJ, Oosterlinck W (2002) Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors. Am J Clin Oncol 25(6 Suppl 1):19-24
7. Vorotnjak M, Boos J, Lanvers-Kaminsky C (2004) In vitro toxicity of bisphosphonates on human neuroblastoma cell lines. Anticancer Drugs 15(8):795-802 (Pubitemid 39281304)
8. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI (2001) The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84(8):126-134
9. Hiraga T, Williams PJ, Mundy GR Yoneda T (2001) The bisphosph-onate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 61(11):4418-4424 (Pubitemid 32685769)
10. Green JR (2002) Bisphosphonates in cancer therapy. Curr Opin Oncol 14(6):609-615 (Pubitemid 35387370)
11. Shipman CM, Rogers MJ, Vanderkerken K, Van Camp B, Graham R, Russell G et al (2000) Bisphosphonates-mechanisms of action in multiple myeloma. Acta Oncol 39(7):829-835
12. Senaratne SG, Colston KW (2002) Direct effects ofbisphospho-nates on breast cancer cells. Breast Cancer Res 4(1):18-23 (Pubitemid 34097552)
13. Yano S, Zhang H, Hanibuchi M, Miki T, Goto H, Uehara H et al (2003) Combined therapy with a new bisphosphonate, minodro-nate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice. Clin Cancer Res 9(14):5380-5385 (Pubitemid 37413593)
14. Virtanen SS, Vaananen HK, Harkonen PL, Lakkakorpi PT (2000) Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 62(9):2708-2714 (Pubitemid 34462756)
15. van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C, Papapoulos S (1996) Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98(3):698-705 (Pubitemid 26349174)
16. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M et al (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone- stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62(22):6538-6544 (Pubitemid 35364119)
17. Boissier S, Magnetto S, Frappart F, Cuzin B, Ebetino FH, Delmas PD et al (1997) Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellularmatrices. Cancer Res 57(18):3890-3894 (Pubitemid 27427670)
18. Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F (2001) The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 12(5):459-465 (Pubitemid 32643090)
19. Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F (2003) The bisphosphonate pamidronate is a potent inhibitor of Ewing's sarcoma cell growth in vitro. Anticancer Drugs 14(9):767-771 (Pubitemid 37357703)
20. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D et al (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339 (6):357-363 (Pubitemid 28363797)
21. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C et al (1996) Efficacy ofpamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335(24):1785-1791 (Pubitemid 26412396)
22. Kanis JA, Powles T, Paterson AH, Mc Closkey EV, Ashley S (1996) Clodronate decreases the frequency ofskeletal metastases in women with breast cancer. Bone 19(6):663-667 (Pubitemid 27035848)
23. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD et al (1991) Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88 (6):2095-2105
24. Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350(16):1655-1664
25. Mohammad KS, Guise TA (2003) Mechanisms of osteoblastic metastases: role of endothelin-1. Clin Orthop Relat Res (415 Suppl):S67-74 (Pubitemid 37323321)
26. Guise TA, Mundy GR (1998) Cancer and bone. Endocr Rev 19 (1):18-54 (Pubitemid 29122073)
27. Choong PF (2003) The molecular basis of skeletal metastases. Clin Orthop Relat Res (415 Suppl):S19-S31
28. Gouin F, Ory B, Rédini F, Heymann D (2006) Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. Int J Cancer 119(5):980-984 (Pubitemid 44116903)